Cancer clinical trials have been the catalyst for many practice changing clinical advances in
oncology [1, 2]. Increasingly, however, there is a realization that (a) the traditional drug …

Uncontrollable metastatic outgrowth process is the leading cause of mortality worldwide,
even in the case of colorectal cancer. Colorectal cancer (CRC) accounts for approximately …

Background Recent molecular characterization of colorectal tumors has identified several
molecular alterations of interest that are considered targetable in metastatic colorectal …

Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …

Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in
the last decade. Survival gains are not driven by advances in first-line therapy but by …

First-, second-, and third-line therapies for the treatment of metastatic colorectal cancer may
influence choices for subsequent therapy. First-line treatment for metastatic colorectal …

Simple Summary The emergence of resistant cells remains a major obstacle for
chemotherapy treatment of metastatic colorectal cancers. Improvement of the therapeutic …

Background An understanding of signaling pathways has not been fully incorporated into
prognostication and therapeutic options. We evaluated the hypothesis that information about …

Choice of first line treatment for patients with metastatic colorectal cancer (mCRC) is based
on tumour and patient related factors and molecular information for determination of …

The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly
improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a …